- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06055920
Lo studio PEERLESS II
PEERLESS II: RCT di FlowTriever rispetto alla sola anticoagulazione nell'embolia polmonare
This study is a prospective, multicenter, randomized controlled trial of the FlowTriever System plus anticoagulation compared to anticoagulation alone for intermediate-risk acute PE.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Effettivo)
Fase
- Non applicabile
Contatti e Sedi
Luoghi di studio
-
-
-
Aalst, Belgio
- Onze Lieve Vrouwziekenhuis
-
-
-
-
British Columbia
-
New Westminster, British Columbia, Canada, V3L 3W7
- Royal Columbian Hospital
-
Surrey, British Columbia, Canada, V3V 1Z2
- Surrey Memorial Hospital
-
Vancouver, British Columbia, Canada, V5Z 1M9
- Vancouver General Hospital
-
-
-
-
-
Aarhus, Danimarca, 8200
- Aarhus University Hospital
-
-
-
-
-
Lille, Francia
- CHU Lille
-
Lyon, Francia
- Hôpital Louis Pradel
-
Marseille, Francia
- Hôpital Nord Marseille
-
Marseille, Francia
- AP-HM Hopital La Timone
-
-
-
-
-
Augsburg, Germania
- University Hospital Augsburg
-
Bad Krozingen, Germania
- Universitäts-Herzzentrum Bad Krozingen
-
Berlin, Germania
- Charité Campus Virchow Clinic - Klinik fuer Radiologie
-
Berlin, Germania
- Unfall Krankenhaus Berlin
-
Cologne, Germania
- University Hospital Cologne
-
Dresden, Germania
- HerzZentrum Dresden Universitaetsklinik
-
Düsseldorf, Germania
- Universitaetsklinikum Dὒsseldorf
-
Essen, Germania
- Universitaetsklinikum Essen
-
Essen, Germania
- Elisabeth Hospital GmbH
-
Frankfurt, Germania
- CCB Frankfurt
-
Hamburg, Germania
- Universitaetsklinikum Hamburg Eppendorf
-
Heidelberg, Germania
- University Hospital - Heidelberg
-
Kaiserslautern, Germania
- Westpfalz Klinikum
-
Munich, Germania
- Klinikum rechts der Isar (TUM)
-
Munich, Germania
- Ludwig Maximilians-University
-
Regensburg, Germania
- University Hospital Regensburg
-
Villingen-Schwenningen, Germania
- Schwarzwald-Baar-Klinikum
-
-
-
-
-
Madrid, Spagna
- Hopital Clinico Universitario San Carlos
-
-
-
-
Alabama
-
Birmingham, Alabama, Stati Uniti, 35243
- Brookwood Medical Center
-
Birmingham, Alabama, Stati Uniti, 35205
- UAB Division of Cardiovascular Disease
-
-
California
-
Pasadena, California, Stati Uniti, 91105
- Huntington Memorial Hospital
-
-
Colorado
-
Aurora, Colorado, Stati Uniti, 80045
- University of Colorado, Denver
-
-
Connecticut
-
New Haven, Connecticut, Stati Uniti, 06520
- Yale University
-
-
Florida
-
Largo, Florida, Stati Uniti, 33770
- HCA FL Largo Medical Center
-
Orlando, Florida, Stati Uniti, 32803
- AdventHealth Orlando
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30322
- Emory University
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60611
- Northwestern University
-
-
Michigan
-
Lansing, Michigan, Stati Uniti, 48910
- McLaren Greater Lansing
-
-
Missouri
-
Kansas City, Missouri, Stati Uniti, 64111
- Saint Luke's Hospital of Kansas City
-
Springfield, Missouri, Stati Uniti, 65804
- Mercy Hospital Springfield
-
-
Nebraska
-
Omaha, Nebraska, Stati Uniti, 68105
- Nebraska Medical Center
-
-
New Jersey
-
Camden, New Jersey, Stati Uniti, 08103
- Virtua Health
-
-
New York
-
Buffalo, New York, Stati Uniti, 14203
- SUNY, The University of Buffalo/Gates Vascular
-
New York, New York, Stati Uniti, 10075
- Northwell Health
-
Rochester, New York, Stati Uniti, 14642
- University of Rochester Medical Center
-
Stony Brook, New York, Stati Uniti, 11794
- Stony Brook University Hospital
-
The Bronx, New York, Stati Uniti, 10467
- Montefiore Medical Center
-
-
Ohio
-
Cincinnati, Ohio, Stati Uniti, 45219
- University of Cincinnati Medical Center
-
Cleveland, Ohio, Stati Uniti, 44195
- The Cleveland Clinic Foundation
-
Columbus, Ohio, Stati Uniti, 43210
- Ohio State University - Wexner Medical Center
-
-
Pennsylvania
-
Bethlehem, Pennsylvania, Stati Uniti, 18015
- St. Luke's University Hospital
-
Erie, Pennsylvania, Stati Uniti, 16507
- UPMC Hamot
-
Erie, Pennsylvania, Stati Uniti, 16505
- AHN Saint Vincent Hospital
-
Harrisburg, Pennsylvania, Stati Uniti, 17101
- UPMC Harrisburg
-
Philadelphia, Pennsylvania, Stati Uniti, 19144
- Thomas Jefferson University
-
Philadelphia, Pennsylvania, Stati Uniti, 19104
- The University of Pennsylvania
-
Pittsburgh, Pennsylvania, Stati Uniti, 15213
- UPMC Heart and Vascular Institute
-
Pittsburgh, Pennsylvania, Stati Uniti, 15212
- Allegheny Health Network Research Institute
-
York, Pennsylvania, Stati Uniti, 17403
- Wellspan York Hospital
-
-
Tennessee
-
Brentwood, Tennessee, Stati Uniti, 37027
- HCA Tristar
-
Knoxville, Tennessee, Stati Uniti, 37920
- UTMC Knoxville
-
Nashville, Tennessee, Stati Uniti, 37203
- Ascension Saint Thomas Hospital
-
-
Texas
-
Dallas, Texas, Stati Uniti, 75235
- Parkland Hospital
-
Fort Worth, Texas, Stati Uniti, 76104
- Texas Health Harris Methodist Hospital
-
San Antonio, Texas, Stati Uniti, 78229
- Methodist Main Hospital
-
Temple, Texas, Stati Uniti, 76508
- Baylor Scott & White - Temple
-
-
Virginia
-
Falls Church, Virginia, Stati Uniti, 22042
- Inova Fairfax
-
-
West Virginia
-
Charleston, West Virginia, Stati Uniti, 25304
- Charleston Area Medical Center
-
Morgantown, West Virginia, Stati Uniti, 26506
- West Virginia University Ruby Memorial Hospital
-
-
Wisconsin
-
Milwaukee, Wisconsin, Stati Uniti, 53215
- Aurora Saint Luke's Medical Center
-
-
-
-
-
Basel, Svizzera
- Universitaetsspital Basel
-
Bern, Svizzera
- Universitätsspital Bern
-
Lucerne, Svizzera
- Luzerner Kantonsspital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
-
Age at enrollment ≥ 18 years
-
Objective evidence of a proximal filling defect in at least one main or lobar pulmonary artery, as confirmed by CTPA, pulmonary angiography, or other imaging modality
-
RV dysfunction, as defined as one or more of the following: RV/LV ratio ≥ 0.9 or RV dilation or hypokinesis
-
At least two additional risk factors, identified by at least one measure in two separate categories noted below:
a. Hemodynamic: i. SBP 90-100mmHg ii. Resting heart rate > 100 bpm b. Biomarker: i. Elevated* cardiac troponin (troponin I or troponin T, conventional or high sensitivity) ii. Elevated* BNP or NT-proBNP iii. Elevated venous lactate ≥2 mmol/L * Elevated, meaning at or above the upper limit of normal, per local standards for the assay used c. Respiratory: i. O2 saturation < 90% on room air ii. Supplemental O2 requirement ≥ 4 L/min iii. Respiratory rate ≥ 20 breaths/min iv. mMRC score > 0
-
Symptom onset within 14 days of confirmed PE diagnosis
-
Willing and able to provide informed consent
Exclusion Criteria:
-
Unable to be anticoagulated with heparin, enoxaparin or other parenteral antithrombin
-
Presentation with hemodynamic instability* that meets the high-risk PE definition in the 2019 ESC Guidelines1, including ANY of the following
- Cardiac arrest OR
- Systolic BP < 90 mmHg or vasopressors required to achieve a BP ≥ 90 mmHg despite adequate filling status, AND end-organ hypoperfusion OR
- Systolic BP < 90 mmHg or systolic BP drop ≥ 40 mmHg, lasting longer than 15 min and not caused by new-onset arrhythmia, hypovolemia, or sepsis * Patients who are stable at time of screening or randomization (i.e., SBP ≥ 90 mmHg and adequate organ perfusion without catecholamine or vasopressor infusion) may be included despite initial presentation including temporary, low-dose catecholamines or vasopressors, or temporary fluid resuscitation.
-
Known sensitivity to radiographic contrast agents that, in the Investigator's opinion, cannot be adequately pre-treated
-
Imaging evidence or other evidence that suggests, in the opinion of the Investigator, the patient is not appropriate for catheter-based intervention (e.g., inability to navigate to target location, clot limited to segmental/subsegmental distribution, predominately chronic clot)
-
End stage medical condition with life expectancy < 3 months, as determined by the Investigator
-
Current participation in another drug or device study that, in the investigator's opinion, would interfere with participation in this study
-
Current or history of chronic thromboembolic pulmonary hypertension (CTEPH) or chronic thromboembolic disease (CTED) diagnosis, per 2019 ESC Guidelines1
-
If objective testing was performed*, estimated RV systolic pressure > 70 mmHg on standard of care echocardiography * If clinical suspicion of acute-on-chronic PE, chronic obstruction, or chronic thromboembolism, echocardiographic estimated RVSP must be confirmed ≤70 mmHg to meet eligibility. Pressure assessment not required if Investigator attests to absence of such clinical suspicion
-
Administration of advanced therapies (thrombolytic bolus, thrombolytic drip/infusion, catheter-directed thrombolytic therapy, mechanical thrombectomy, or ECMO) for the index PE event within 30 days prior to enrollment
-
Ventricular arrhythmias refractory to treatment at the time of enrollment
-
Known to have heparin-induced thrombocytopenia (HIT)
-
Subject has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (e.g., compromise the well-being or that could prevent, limit, or confound the protocol-specified assessments). This includes a contraindication to use of FlowTriever System per local approved labeling
-
Subject is currently pregnant
-
Subject has previously completed or withdrawn from this study
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Comparatore attivo: FlowTriever
Mechanical thrombectomy for pulmonary embolism using the FlowTriever System. |
Mechanical Thrombectomy for pulmonary embolism |
|
Comparatore attivo: Anticoagulation
Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc. Anticoagulants are a group of medications that decrease your blood's ability to clot. |
Commercially available/market approved anticoagulation medication including but not limited to: Heparin Sodium, Coumadin, Rivaroxaban, Apixaban, etc. Anticoagulants are a group of medications that decrease your blood's ability to clot. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Composite clinical endpoint constructed as a win ratio, a hierarchy of the following, which are assessed post-randomization:
Lasso di tempo: through discharge or 30 days, whichever is sooner / dyspnea at 48 hours
|
|
through discharge or 30 days, whichever is sooner / dyspnea at 48 hours
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Mortalità per tutte le cause e correlata all’EP
Lasso di tempo: A 30 e 90 giorni
|
A 30 e 90 giorni
|
|
|
Riammissioni per tutte le cause e per EP
Lasso di tempo: A 30 e 90 giorni
|
A 30 e 90 giorni
|
|
|
6 minuti a piedi
Lasso di tempo: Alla visita di 1 mese
|
Alla visita di 1 mese
|
|
|
Rapporto VD/VS
Lasso di tempo: Alla visita delle 48 ore
|
Alla visita delle 48 ore
|
|
|
Diagnosi di disabilità post-PE (PPEI)
Lasso di tempo: Attraverso la visita di 3 mesi
|
Attraverso la visita di 3 mesi
|
|
|
Composite clinical endpoint constructed as a win ratio hierarchy of the following three components, assessed post randomization:
Lasso di tempo: up to 30 days
|
|
up to 30 days
|
|
Clinical deterioration
Lasso di tempo: Through discharge or up to 30 days after randomization, whichever is sooner
|
defined by hemodynamic or respiratory worsening |
Through discharge or up to 30 days after randomization, whichever is sooner
|
|
Bailout therapy
Lasso di tempo: Through discharge or up to 30 days after randomization, whichever is sooner
|
either after a deterioration or after documented failure to progress, |
Through discharge or up to 30 days after randomization, whichever is sooner
|
|
Major Bleeding, defined by the Bleeding Academic Research Consortium (BARC), level 3b, 3c, 5a, or 5b
Lasso di tempo: At 30 and 90 days
|
3b: Overt bleeding plus hemoglobin drop of ≥ 5 g/dL (provided hemoglobin drop is related to bleed); cardiac tamponade, bleeding requiring surgical intervention for control (excluding dental/nasal/skin/hemorrhoid); bleeding requiring intravenous vasoactive agents 3c: Intracranial hemorrhage (does not include microbleeds or hemorrhagic transformation, does include intraspinal), subcategories confirmed by autopsy or imaging or lumbar puncture, intraocular bleed compromising vision. 5a: Probable fatal bleeding; no autopsy or imaging confirmation but clinically suspicious 5b: Definite fatal bleeding; overt bleeding or autopsy or imaging confirmation |
At 30 and 90 days
|
|
Dyspnea severity by mMRC score
Lasso di tempo: At the 48-hour, 1-month, and 3-month visits
|
0, no breathlessness except on strenuous exercise;
|
At the 48-hour, 1-month, and 3-month visits
|
|
PE-related quality of life, by PEmb-QoL
Lasso di tempo: At the 1- and 3-month visits
|
Pulmonary Embolism Quality of Life: (higher = better) |
At the 1- and 3-month visits
|
|
General health-related quality of life, by EQ-5D-5L
Lasso di tempo: At the 1- and 3-month visits
|
Higher score = worse |
At the 1- and 3-month visits
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Jay Giri, MD, Penn Medicine
- Investigatore principale: Bernhard Gebauer, MD, Charité University Hospital Berlin
- Investigatore principale: Felix Mahfoud, MD, Universitaetsspital Basel
- Investigatore principale: Frances Mae West, MD, Jefferson Health
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 23-001
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
prodotto fabbricato ed esportato dagli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .